Brokers Set Expectations for ProMIS Neurosciences, Inc.’s FY2024 Earnings (NASDAQ:PMN)

ProMIS Neurosciences, Inc. (NASDAQ:PMN) – Investment analysts at Leede Jones Gab upped their FY2024 earnings per share estimates for shares of ProMIS Neurosciences in a research note issued to investors on Monday, July 29th. Leede Jones Gab analyst D. Loe now anticipates that the company will earn ($0.24) per share for the year, up from their previous estimate of ($1.11). The consensus estimate for ProMIS Neurosciences’ current full-year earnings is ($0.24) per share. Leede Jones Gab also issued estimates for ProMIS Neurosciences’ FY2025 earnings at ($0.21) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.10) EPS and FY2028 earnings at $0.17 EPS.

ProMIS Neurosciences Trading Down 7.6 %

Shares of NASDAQ PMN opened at $1.33 on Thursday. ProMIS Neurosciences has a 12-month low of $0.95 and a 12-month high of $3.50. The company has a market cap of $25.22 million, a P/E ratio of -1.80 and a beta of 0.65. The stock has a fifty day moving average price of $1.76 and a 200 day moving average price of $1.93.

ProMIS Neurosciences (NASDAQ:PMN) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.